Literature DB >> 23797153

Paxillin phosphorylation counteracts proteoglycan-mediated inhibition of axon regeneration.

Tomoharu Kuboyama1, Xueting Luo, Kevin Park, Murray G Blackmore, Takuro Tojima, Chihiro Tohda, John L Bixby, Vance P Lemmon, Hiroyuki Kamiguchi.   

Abstract

In the adult central nervous system, the tips of axons severed by injury are commonly transformed into dystrophic endballs and cease migration upon encountering a rising concentration gradient of inhibitory proteoglycans. However, intracellular signaling networks mediating endball migration failure remain largely unknown. Here we show that manipulation of protein kinase A (PKA) or its downstream adhesion component paxillin can reactivate the locomotive machinery of endballs in vitro and facilitate axon growth after injury in vivo. In dissociated cultures of adult rat dorsal root ganglion neurons, PKA is activated in endballs formed on gradients of the inhibitory proteoglycan aggrecan, and pharmacological inhibition of PKA promotes axon growth on aggrecan gradients most likely through phosphorylation of paxillin at serine 301. Remarkably, pre-formed endballs on aggrecan gradients resume forward migration in response to PKA inhibition. This resumption of endball migration is associated with increased turnover of adhesive point contacts dependent upon paxillin phosphorylation. Furthermore, expression of phosphomimetic paxillin overcomes aggrecan-mediated growth arrest of endballs, and facilitates axon growth after optic nerve crush in vivo. These results point to the importance of adhesion dynamics in restoring endball migration and suggest a potential therapeutic target for axon tract repair.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aggrecan; Axon regeneration; Dystrophic endball; Optic nerve; Paxillin; Point contact; Protein kinase A; p21-activated kinase

Mesh:

Substances:

Year:  2013        PMID: 23797153      PMCID: PMC3773816          DOI: 10.1016/j.expneurol.2013.06.011

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  64 in total

Review 1.  cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes.

Authors:  S S Taylor; J A Buechler; W Yonemoto
Journal:  Annu Rev Biochem       Date:  1990       Impact factor: 23.643

Review 2.  Studies of the mechanism of action and regulation of cAMP-dependent protein kinase.

Authors:  J Granot; A S Mildvan; E T Kaiser
Journal:  Arch Biochem Biophys       Date:  1980-11       Impact factor: 4.013

3.  Reversible autophosphorylation of type II cAMP-dependent protein kinase: distinction between intramolecular and intermolecular reactions.

Authors:  J Erlichman; R Rangel-Aldao; O M Rosen
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

4.  Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes.

Authors:  R J McKeon; R C Schreiber; J S Rudge; J Silver
Journal:  J Neurosci       Date:  1991-11       Impact factor: 6.167

5.  Self-amplifying autocrine actions of BDNF in axon development.

Authors:  Pei-Lin Cheng; Ai-Hong Song; Yu-Hui Wong; Sheng Wang; Xiang Zhang; Mu-Ming Poo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

6.  Combinatorial therapy with neurotrophins and cAMP promotes axonal regeneration beyond sites of spinal cord injury.

Authors:  Paul Lu; Hong Yang; Leonard L Jones; Marie T Filbin; Mark H Tuszynski
Journal:  J Neurosci       Date:  2004-07-14       Impact factor: 6.167

7.  Phosphorylation of RII subunit and attenuation of cAMP-dependent protein kinase activity by proline-directed protein kinase.

Authors:  R K Braun; P R Vulliet; D A Carbonaro-Hall; F L Hall
Journal:  Arch Biochem Biophys       Date:  1991-08-15       Impact factor: 4.013

8.  Studies on the development and behavior of the dystrophic growth cone, the hallmark of regeneration failure, in an in vitro model of the glial scar and after spinal cord injury.

Authors:  Veronica J Tom; Michael P Steinmetz; Jared H Miller; Catherine M Doller; Jerry Silver
Journal:  J Neurosci       Date:  2004-07-21       Impact factor: 6.167

9.  The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery.

Authors:  Elena Nikulina; J Lille Tidwell; Hai Ning Dai; Barbara S Bregman; Marie T Filbin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

10.  cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury.

Authors:  Damien D Pearse; Francisco C Pereira; Alexander E Marcillo; Margaret L Bates; Yerko A Berrocal; Marie T Filbin; Mary Bartlett Bunge
Journal:  Nat Med       Date:  2004-05-23       Impact factor: 53.440

View more
  5 in total

Review 1.  The Biology of Regeneration Failure and Success After Spinal Cord Injury.

Authors:  Amanda Phuong Tran; Philippa Mary Warren; Jerry Silver
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

2.  Astrocyte spreading and migration on aggrecan-laminin dot gradients.

Authors:  Tony W Hsiao; Patrick A Tresco; Vladimir Hlady
Journal:  Biointerphases       Date:  2017-09-11       Impact factor: 2.456

Review 3.  Repair of spinal cord injury with neuronal relays: From fetal grafts to neural stem cells.

Authors:  Joseph F Bonner; Oswald Steward
Journal:  Brain Res       Date:  2015-01-12       Impact factor: 3.252

Review 4.  Paxillin: a crossroad in pathological cell migration.

Authors:  Ana María López-Colomé; Irene Lee-Rivera; Regina Benavides-Hidalgo; Edith López
Journal:  J Hematol Oncol       Date:  2017-02-18       Impact factor: 17.388

5.  Ischemic injury leads to extracellular matrix alterations in retina and optic nerve.

Authors:  Jacqueline Reinhard; Marina Renner; Susanne Wiemann; Daniel A Shakoor; Gesa Stute; H Burkhard Dick; Andreas Faissner; Stephanie C Joachim
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.